Actively Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Led by Novartis Pharmaceuticals · Updated on 2026-03-11
315
Participants Needed
25
Research Sites
373 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this 2-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response \[CRR\] or partial renal response \[PRR\]) on double-blind treatment at the end of the SIRIUS-LN core study, and 2. of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.
CONDITIONS
Official Title
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before joining the extension study
- Completed the entire treatment in the SIRIUS-LN core study up to Week 144 on double-blind or open-label treatment
You will not qualify if you...
- Use of therapies not allowed in this study
- Pregnant or nursing (lactating) women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 25 locations
1
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil, 40150 150
Actively Recruiting
2
Novartis Investigative Site
Shantou, Guangdong, China, 515000
Active, Not Recruiting
3
Novartis Investigative Site
Liuzhou, Guangxi, China, 545005
Actively Recruiting
4
Novartis Investigative Site
Wuhan, Hubei, China, 430060
Actively Recruiting
5
Novartis Investigative Site
Binzhou, Shandong, China, 256603
Actively Recruiting
6
Novartis Investigative Site
Beijing, China, 100034
Actively Recruiting
7
Novartis Investigative Site
Guangzhou, China, 510080
Actively Recruiting
8
Novartis Investigative Site
Guangzhou, China, 510280
Actively Recruiting
9
Novartis Investigative Site
Shanghai, China, 200080
Actively Recruiting
10
Novartis Investigative Site
Barranquilla, Atlántico, Colombia, 080020
Actively Recruiting
11
Novartis Investigative Site
Budapest, Hungary, H-1097
Actively Recruiting
12
Novartis Investigative Site
León, Guanajuato, Mexico, 37160
Actively Recruiting
13
Novartis Investigative Site
Oaxaca City, Mexico, 68020
Actively Recruiting
14
Novartis Investigative Site
Querétaro, Mexico, 76070
Actively Recruiting
15
Novartis Investigative Site
Bucharest, Romania, 022328
Actively Recruiting
16
Novartis Investigative Site
Singapore, Singapore, 169608
Actively Recruiting
17
Novartis Investigative Site
Singapore, Singapore, S308433
Actively Recruiting
18
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea, 16499
Actively Recruiting
19
Novartis Investigative Site
Seoul, South Korea, 03722
Actively Recruiting
20
Novartis Investigative Site
Seoul, South Korea, 04763
Actively Recruiting
21
Novartis Investigative Site
Taichung, Taiwan, 40447
Actively Recruiting
22
Novartis Investigative Site
Songkhla, Hat Yai, Thailand, 90110
Actively Recruiting
23
Novartis Investigative Site
Bangkok, Thailand, 10330
Actively Recruiting
24
Novartis Investigative Site
Bangkok, Thailand, 10400
Actively Recruiting
25
Novartis Investigative Site
Chiang Mai, Thailand, 50200
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here